Biocryst Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2013.
“We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.
Help employers find you! Check out all the jobs and post your resume.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2013.
“We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.
Help employers find you! Check out all the jobs and post your resume.